Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...
China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised...
China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...
Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...
China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...
US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...
China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...
China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...
The Fujian drug and device joint procurement center has released two separate notifications regarding the...
The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...
China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...